scholarly journals Natriuretic Peptides and Analytical Barriers

2017 ◽  
Vol 63 (1) ◽  
pp. 50-58 ◽  
Author(s):  
Vlad C Vasile ◽  
Allan S Jaffe
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Myocardial Function ◽  
Specific Assay ◽  
Peptide System ◽  
Cardiovascular Homeostasis ◽  
Natriuretic Peptide System

Abstract BACKGROUND The natriuretic peptide system is an endocrine, autocrine and paracrine system that plays an important role in the maintenance of cardiovascular homeostasis. Biomarkers based on these peptides are important diagnostic and prognostic tools for myocardial function. CONTENT Although natriuretic peptides were discovered more than 2 decades ago, their intricate and complex biology is associated with important questions not yet elucidated. The diversity of circulating forms of natriuretic peptides, the distinct expression of these forms in particular patients, and the heterogeneity of heart failure forms, along with specific assay-related and preanalytic issues, cause assays to be poorly harmonized. SUMMARY This review presents the relevant issues related to the biology of natriuretic peptides and differences between assays with immediate implications for clinical practice.

Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure

Circulation ◽  
1997 ◽  
Vol 96 (2) ◽  
pp. 509-516 ◽  
Author(s):  
Takayoshi Tsutamoto ◽  
Atsuyuki Wada ◽  
Keiko Maeda ◽  
Tomoko Hisanaga ◽  
Yukiharu Maeda ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Peptide System ◽  
Natriuretic Peptide System

Natriuretic peptide system is not exhausted in severe heart failure

2009 ◽  
Vol 10 (1) ◽  
pp. 39-43 ◽  
Author(s):  
Patrícia Lourenço ◽  
Ana Azevedo ◽  
José Paulo Araújo ◽  
Paulo Bettencourt
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Severe Heart Failure ◽  
Peptide System ◽  
Natriuretic Peptide System

Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs

2000 ◽  
Vol 278 (1) ◽  
pp. H33-H40 ◽  
Author(s):  
John G. Lainchbury ◽  
John C. Burnett ◽  
Donna Meyer ◽  
Margaret M. Redfield
Keyword(s):  
Heart Failure ◽  
Diastolic Function ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Myocardial Function ◽  
Diastolic Pressure ◽  
Arterial Elastance ◽  
Inotropic Effects ◽  
End Diastolic Volume ◽  
Systolic And Diastolic Function

The effects on myocardial function and loading conditions of clinically relevant doses of the natriuretic peptides (NP) have not been established. The actions of single doses (100 ng ⋅ kg− 1 ⋅ min− 1iv over 30 min) of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) were studied in conscious normal dogs and in dogs with pacing-induced heart failure. All three NP reduced end-diastolic pressure in normal dogs, and ANP and BNP reduced end-diastolic volume. In heart failure ANP and BNP reduced EDP, and ANP reduced EDV. Arterial elastance was unchanged in normal dogs and in dogs with heart failure. ANP increased end-systolic elastance ( E es) in normal dogs, whereas BNP tended to increase E es ( P = 0.06). In dogs with heart failure, no inotropic effect was seen. In normal dogs, all NP reduced the time constant of isovolumic relaxation (τ), and ANP and BNP reduced τ in dogs with heart failure. Increases in plasma cGMP in dogs with heart failure were blunted. The NP reduced preload and enhanced systolic and diastolic function in normal dogs. Effects of ANP and BNP on preload and diastolic function were maintained in heart failure. Lack of negative inotropic effects in heart failure supports the validity of the NP as therapeutic agents.

Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance

2004 ◽  
Vol 102 (3) ◽  
pp. 223-241 ◽  
Author(s):  
Zaid Abassi ◽  
Tony Karram ◽  
Samer Ellaham ◽  
Joseph Winaver ◽  
Aaron Hoffman
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Peptide System ◽  
Natriuretic Peptide System

Designer natriuretic peptides: a vision for the future of heart failure therapeutics

2011 ◽  
Vol 89 (8) ◽  
pp. 593-601 ◽  
Author(s):  
Rosita Zakeri ◽  
John C. Burnett
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
The Novel ◽  
Heart Failure Therapy ◽  
Therapeutic Benefits ◽  
Peptide System ◽  
Chimeric Peptides

Despite recent pharmacological advances in heart failure therapy, mortality from acute decompensated heart failure remains high. Conventional therapies are often insufficient to address the complex interplay between structural, functional, neurohumoral, and renal mechanisms involved in the heart failure syndrome. The natriuretic peptide system, however, offers a unique pleiotropic strategy which could bridge this gap in heart failure therapy. Exogenous administration of native A-type and B-type natriuretic peptides has been met with both success and limitations, and despite the limitations, remains a worthwhile endeavor. Alternatively, synthetic modification to create “designer” chimeric peptides holds the possibility to extend both the application and therapeutic benefits possible with a natriuretic peptide based approach. Herein we describe the development of natriuretic peptide based heart failure therapies, including the design, rationale, and preliminary studies of the novel chimeric peptides CD-NP and CU-NP.

Sign in / Sign up

Export Citation Format

Share Document